HGI-001 / BGI Group - LARVOL DELTA

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia (clinicaltrials.gov) - P1 | N=3 | Recruiting | Sponsor: Shenzhen Hemogen | Trial completion date: Aug 2025 ➔ Dec 2025 | Trial primary completion date: Aug 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Beta-Thalassemia • Genetic Disorders

Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients. (clinicaltrials.gov) - P1 | N=8 | Recruiting | Sponsor: Shenzhen Hemogen

New P1 trial • Beta-Thalassemia • Genetic Disorders

INTERIM RESULTS OF GENE THERAPY USING OPTIMIZED LENTIHBBT87Q VECTOR IN FIVE CHINESE PATIENTS WITH TRANSFUSION DEPENDENT Β-THALASSEMIA (EHA 2024) - P1 | "Patients undergo HSC mobilization usinggranulocyte colony-stimulating factor (G-CSF) and plerixafor...Subsequently, patients receive myeloablative conditioning withpharmacokinetic-adjusted busulfan over a period of 4 days, followed by infusion of HGI-001 Injection... Gene therapy with optimized LentiHBBT87Q vector assist five Chinese TDT patients become transfusion-independent without special concerned serious adverse events related to gene therapy."

Clinical • Gene therapy • Beta-Thalassemia • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Pediatrics • Transplantation • CD34

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia (clinicaltrials.gov) - P1 | N=3 | Recruiting | Sponsor: Shenzhen Hemogen

New P1 trial • Genetic Disorders